CTOs on the Move

GN Resound

www.gnresound.com

 
GN ReSound is the undisputed technology leader in the global hearing instrument market and is one of several divisions of GN Great Nordic. To learn more about our parent company, Great Nordic, please click on the link below.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.gnresound.com
  • 8001 E Bloomington Fwy
    Minneapolis, MN USA 55420
  • Phone: 952.769.8000

Executives

Name Title Contact Details

Similar Companies

Gateway EDI Inc

Gateway EDI Inc is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cardio-Respiratory Assistance

Cardio-Respiratory Assistance is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dimensions Healthcare System

Dimensions Healthcare System is an integrated not-for-profit, community-owned organization comprised of two hospitals and several other healthcare facilities providing comprehensive, quality healthcare services to the residents of Prince George`s County, Maryland and surrounding areas. Both hospitals within Dimensions Healthcare System have been recognized by U.S. News & World Report. Dimensions Healthcare System is the largest healthcare system headquartered in Prince George`s County.

Hoya Vision

Driven by a passion for partnership as well as innovation, HOYA has been a partner to Eye Care Professionals for over 75 years, enabling them to give people the greatest gift, the gift of vision. We provide Eye Care Professionals with the lenses, consultation solutions and other services that help them to develop their practice while changing the way people see the world. We see them as visionaries, and everything we do is for them. Founded in Japan in 1941, today, HOYA has a presence in over 80 countries across the globe.

Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.